| Title |
Control of Arthritis Pain with Anti–Nerve-Growth Factor: Risk and Benefit
|
|---|---|
| Published in |
Current Rheumatology Reports, September 2012
|
| DOI | 10.1007/s11926-012-0289-8 |
| Pubmed ID | |
| Authors |
Matthias F. Seidel, Nancy E. Lane |
| Abstract |
Arthritis is characterized by pain and inflammation. Recently, attention has been focused on nerve-growth factor (NGF), a neurotrophin that is a key regulator of peripheral nociception because it mediates overexpression of proinflammatory neuron-derived molecules such as substance P, serotonin, and calcitonin gene-related peptide. Antibodies have been generated for NGF and its receptor that are effective in reducing pain in preclinical pain models, and clinical trials in patients with advanced knee and hip osteoarthritis and low-back pain. Results show pain reduction is rapid and sustained. Adverse events with anti-NGF included transient paraesthesia and edema, rapidly progressive OA, and, in a small number of patients treated with both anti-NGF and nonsteroidal anti-inflammatory drugs, osteonecrosis. Inhibition of the NGF-stimulated nociceptive pathway seems to be effective; however, the adverse effects require further investigation. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 80 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Denmark | 1 | 1% |
| Unknown | 79 | 99% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 12 | 15% |
| Student > Master | 11 | 14% |
| Researcher | 7 | 9% |
| Student > Postgraduate | 7 | 9% |
| Student > Doctoral Student | 6 | 8% |
| Other | 18 | 23% |
| Unknown | 19 | 24% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 26 | 33% |
| Agricultural and Biological Sciences | 12 | 15% |
| Nursing and Health Professions | 5 | 6% |
| Engineering | 4 | 5% |
| Neuroscience | 3 | 4% |
| Other | 8 | 10% |
| Unknown | 22 | 28% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 09 September 2012.
All research outputs
#20,166,700
of 22,678,224 outputs
Outputs from Current Rheumatology Reports
#634
of 706 outputs
Outputs of similar age
#151,030
of 169,211 outputs
Outputs of similar age from Current Rheumatology Reports
#8
of 8 outputs
Altmetric has tracked 22,678,224 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 706 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.0. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 169,211 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 8 others from the same source and published within six weeks on either side of this one.